Clareo Health | Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zhejiang Cancer Hospital
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed non-small cell lung cancer
≤3 metastatic organs and ≤5 metastatic lesions (supraclavicular and mediastinal lymph nodes are not classified as distant metastasis; other lymph node
metastasis一group lymph node region will be classified as one metastatic lesion）
Tissue biopsy prior to treatment
ECOG performance score 0-1
You may not be if
EGFR mutation or ALK positive.
Evidence on pulmonary interstitial disease or symptoms of active non-infectious pneumonia.
Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus.
Previous treatment with antibody against pd -1, pd - L1, pd - L2, CD137 or CTLA-4 (including ipilimumab or any antibody or drug against T cell co-stimulation or checkpoint pathway).
